Abstract
Adjuvant chemotherapy is recommended for all patients with stage III colorectal cancer (CRC) and stage II with unfavorable prognosis factors. To optimize the administration of adjuvant chemotherapy, it is necessary to study markers of high risk of progression. According to the literature data, the prognostic role of circulating tumor DNA (ctDNA) after surgery is shown. The aim of our research was to study the prognostic role of the ctDNA in patients with stage I-III CRC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
